InMed Pharmaceuticals (INM) Stock Statistics & Valuation Metrics

InMed Pharmaceuticals has a market cap or net worth of $5.22M. The enterprise value is -$3.87M.

InMed Pharmaceuticals has 2,384,186 shares outstanding. The number of shares has decreased by -2.65% in one year.

InMed Pharmaceuticals’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -56.08%.

The current PE Ratio of InMed Pharmaceuticals is ―. InMed Pharmaceuticals’s PEG ratio is 0.00002.

In the last 12 months, InMed Pharmaceuticals had revenue of 4.94B and earned -8.16B in profits. Earnings per share was -8.36.

In the last 12 months, operating cash flow was -7.82B and capital expenditures 0.00, giving a free cash flow of -7.82B billion.

InMed Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

InMed Pharmaceuticals upcoming earnings date is Nov 13, 2025, Before Open (Confirmed).

InMed Pharmaceuticals as a current ratio of 6.99, with Debt / Equity ratio of 2.28%

In the past 12 months, InMed Pharmaceuticals has paid 0.00 in taxes.

InMed Pharmaceuticals EV to EBITDA ratio is 1.44, with an EV/FCF ratio of 1.39K.

InMed Pharmaceuticals has $11.12B in cash and marketable securities with $305.75M in debt, giving a net cash position of $10.81B billion.

Gross margin is 34.53%, with operating margin of -155.89%, and net profit margin of -165.14%.

The average price target for InMed Pharmaceuticals is $2.50, which is 11.43% higher than the current price. The consensus rating is Moderate Sell